CTLA4 and neoplasm: CTLA-4 suppresses T cell activity and inhibits immune responses by inhibiting the binding of the costimulatory molecules CD80 or CD86, found on the surface of antigen-presenting cells (APCs) in the tumor-draining lymph nodes (TDLNs), to the coactivation receptor CD28 [61].